Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Liabilities and Shareholders Equity: 2023-2024

Historic Liabilities and Shareholders Equity for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $38.9 million.

  • BioLineRx's Liabilities and Shareholders Equity fell 33.02% to $43.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $178.4 million, marking a year-over-year decrease of 23.41%. This contributed to the annual value of $38.9 million for FY2024, which is 39.14% down from last year.
  • Latest data reveals that BioLineRx reported Liabilities and Shareholders Equity of $38.9 million as of FY2024, which was down 39.14% from $63.9 million recorded in FY2023.
  • BioLineRx's Liabilities and Shareholders Equity's 5-year high stood at $63.9 million during FY2023, with a 5-year trough of $38.9 million in FY2024.
  • Over the past 2 years, BioLineRx's median Liabilities and Shareholders Equity value was $51.4 million (recorded in 2023), while the average stood at $51.4 million.
  • Data for BioLineRx's Liabilities and Shareholders Equity shows a maximum YoY slumped of 39.14% (in 2024) over the last 5 years.
  • BioLineRx's Liabilities and Shareholders Equity (Yearly) stood at $63.9 million in 2023, then slumped by 39.14% to $38.9 million in 2024.